[1] A. Silman et al., “Proposal to establish a register for the long term surveillance of adverse events in patients with rheumatic diseases exposed to biological agents: the EULAR Surveillance Register for Biological Compounds,” Ann. Rheum. Dis., vol. 59, no. 6, pp. 419–420, 2000.
[2] M. L. D. et al. R. James R., John B, CURRENT Diagnosis and Treatment Rheumatology 3rd ED. Mc Graw Hill education. 2013.
[3] G. S. et al Firestein GS, Budd RC, etiology and pathogenesis. In: Kelley's Textbook of Rheumatology.9thEd. China, Elsevier. 2013.
[4] R. S. W. B. et al Doherty M, Musculoskeletal disorders. In: Davidson’s Principles and Practice of Medicine. 21th Ed. London, Elsevier’s Health Sciences Rights Department. 2010.
[5] A.-A. F. et al Al-Rawi ZS, Alazzawi AJ, “Rheumatoid Arthritis in population samples in Iraq,” Ann Rheum Dis, vol. 37, no. 1, pp. 73–75, 1978.
[6] Al-Saadawi TH., "The association of smoking with disease activity and appearance of extra-articular manifestation in RA patients.," Post-- Grad. Med. J., vol. 12, no. 1, pp. 146–152, 2013.
[7] F. G. Sweney SE., Harris ED, Clinical features of rheumatoid arthritis. Kelley’s Textbook of Rheumatology. 9thEd. China, Elsevier. 2013.
[8] D. Aletaha et al., “2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative,” Arthritis Rheum., vol. 62, no. 9, pp. 2569–2581, 2010.
[9] I. D. Nizar Abdulateef Jassim, Efficacy, Safety and Predictors of response to Etanercept in Treatment of Iraqi Patients with Active RA. Diploma thesis. The University of Baghdad, College of Medicine, Rheumatology Unit. 2013.
[10] M. D. et al Sonya Abraham, Andrew Barr, Arthritis. In Rheumatology Handbook.Imperial College, Press. 2012.
[11] J. S. Smolen et al., “EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs,” Ann. Rheum. Dis., vol. 69, no. 6, pp. 964–975, 2010.
[12] M.-J. C. J. Guerry et al., “Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis,” Rheumatology, vol. 51, no. 4, pp. 634–643, 2011.
[13] M. com/drug/Rituxan. Rituximab-342243, "Rituxan (rituximab) dosing, indications, interactions, adverse effects and more. Available from URL:http:/ www. Reference.".
[14] M. J. W. M. Oqbro O. PharmD., "Rituxan Drug Facts, Side Effects, and Dosing, cancer center, cancer a-z list, RTX index, Rituxan drug monograph.," 2016.
[15] J. C. W. Edwards et al., “Efficacy of B-cell–targeted therapy with rituximab in patients with rheumatoid arthritis,” N. Engl. J. Med., vol. 350, no. 25, pp. 2572–2581, 2004.
[16] M. F. Luca Q, Sara S., “Cost saving and predictive factors of response to RTX in RA: Salvatore De Vita, Clinic of Rheumatology, University Hospital of Udine, Piazzale S. Maria della Misericordia,” 2012.
[17] A. Richter et al., "Sustainability of Rituximab Therapy in Different Treatment Strategies: Results of a 3‐Year Follow-up of a German Biologics Register," Arthritis Care Res. (Hoboken)., vol. 66, no. 11, pp. 1627–1633, 2014.
[18] R. F. van Vollenhoven, R. M. Fleischmann, D. E. Furst, S. Lacey, and P. B. Lehane, "Longterm safety of rituximab: final report of rheumatoid arthritis global clinical trial program over 11 years," J. Rheumatol., vol. 42, no. 10, pp. 1761–1766, 2015.
[19] A. Khan, D. L. Scott, and M. Batley, “Smoking, rheumatoid factor status and responses to rituximab,” Ann. Rheum. Dis., vol. 71, no. 9, pp. 1587–1588, 2012.
[20] M. A. Lopez-Olivo, M. Amezaga Urruela, L. Mcgahan, E. N. Pollono, and M. E. Suarez-Almazor, “Rituximab for rheumatoid arthritis,” Cochrane Database Syst. Rev., vol. 2017, no. 6, pp. 99–111, 2015.
[21] J. D. Isaacs et al., “Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis,” Ann. Rheum. Dis., vol. 72, no. 3, pp. 329–336, 2013.
[22] J. Wendler et al., “Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients,” Arthritis Res. Ther., vol. 16, no. 2, p. R80, 2014.
[23] J. Sellam et al., “B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six‐month, national, multicenter, open‐label study,” Arthritis Rheum., vol. 63, no. 4, pp. 933–938, 2011.
[24] R. van Vollenhoven et al., “long-term Safety Of Rituximab: Pooled Analysis Of The Rheumatoid Arthritis Global Clinical Trial Program Over 11 Years.: 2342,” Arthritis Rheum., vol. 65, p. S1000, 2013.
[25] D. Ennishi et al., “Does rituximab really induce hepatitis C virus reactivation?,” J. Clin. Oncol., vol. 26, no. 28, pp. 4695–4696, 2008.